Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease. 1984

M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat

A prospective study was undertaken in 1963 on the respective prognostic significances of erythrocyte sedimentation rate (ESR) and presence or absence of systemic symptoms in Hodgkin's disease. Six hundred seventy-six patients with clinical stages I or II were included in this study; 376 from 1963 to 1971 who were included in the H1 trial of the European Organization for Research and Treatment of Cancer (EORTC) and 300 who had been enrolled in the EORTC H2 trial from 1972 to 1976. All relevant data and long-term follow-up are available from 649 patients who were analyzed in this study. Multivariate analysis (Cox model) was carried out to assess the prognostic value of ESR independently of the other prognostic parameters and of the treatment. The results showed that of all the prognostic indicators studied, ESR is the one which has the highest correlation with relapse-free survival; however, initial ESR is not correlated with the probability of death after relapse. The presence or absence of systemic symptoms has less prognostic impact. Despite a close correlation between systemic symptoms and ESR, the two are not redundant and it is useful to combine both.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001799 Blood Sedimentation Measurement of rate of settling of ERYTHROCYTES in blood. Erythrocyte Sedimentation,Erythrocyte Sedimentation Rate,Erythrocyte Sedimentation Rates,Rate, Erythrocyte Sedimentation,Rates, Erythrocyte Sedimentation,Sedimentation Rate, Erythrocyte,Sedimentation Rates, Erythrocyte,Sedimentation, Blood,Sedimentation, Erythrocyte
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative

Related Publications

M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
May 1983, Meditsinskaia sestra,
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
June 1973, Vrachebnoe delo,
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
September 2021, Revista da Associacao Medica Brasileira (1992),
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
September 1955, Minerva medica,
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
August 1965, The American journal of the medical sciences,
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
January 1987, The Journal of bone and joint surgery. American volume,
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
June 1987, The Journal of bone and joint surgery. American volume,
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
January 1955, Acta medica Scandinavica,
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
August 1986, Archives of internal medicine,
M Tubiana, and M Henry-Amar, and M V Burgers, and B van der Werf-Messing, and M Hayat
April 1995, The Journal of rheumatology,
Copied contents to your clipboard!